Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Gastroenterol Insights. 2023 Sep 28;14(4):420–430. doi: 10.3390/gastroent14040031

Table 2.

Adverse reactions reported by 4% or more of patients treated with terlipressin.

Adverse Event Placebo % Terlipressin %
Abdominal pain 6.1 19.5
Nausea 10.1 16.0
Respiratory failure 7.1 15.5
Diarrhea 7.1 13.0
Dyspnea 5.1 12.5
Fluid overload 3.0 8.5
Pleural effusion 0 5.5
Sepsis 1.0 5.5
Bradycardia 0 5.0
Ischemia-related events (skin discoloration, cyanosis, ischemia, and intestinal ischemia) 0 4.5

Reprint from Refs. [25,30].